First-in-class drug approvals
China, 2022 to 2025
11
2025
First-in-class drug approvals: China, 2022 to 2025
First-in-class drug approvals: China, 2022 to 2025. 4 observations from 2022 to 2025, ranging from 11 to 48. Latest value 11 (2025).
0
10
20
30
40
50
2022
2023
2024
2025
21
11
First-in-class drug approvals: China, 2022 to 2025
First-in-class drug approvals: China, 2022 to 2025. 4 observations from 2022 to 2025, ranging from 11 to 48. Latest value 11 (2025).
0
20
40
60
2022
2023
2024
2025
21
11
First-in-class drug approvals: China, 2022 to 2025
First-in-class drug approvals: China, 2022 to 2025. 4 observations from 2022 to 2025, ranging from 11 to 48. Latest value 11 (2025).
0
20
40
60
2022
2023
2024
2025
21
11
View the underlying data
First-in-class drug approvals: China, 2022 to 2025
Period
Type
Value
2022
Actual
21
2023
Actual
40
2024
Actual
48
2025
Actual
11
Chart:
StatOrigin
· Source: NMPA, NHSA ·
statorigin.org
CC BY 4.0